Dry AMD Treatment: VALEDA Light Therapy
First in San Francisco to offer VALEDA® for Dry AMD.
VALEDA® Light Delivery System is the first and only FDA-authorized treatment for Dry Age-Related Macular Degeneration (AMD) shown in clinical trials to improve visual acuity.
VALEDA utilizes photobiomodulation (PBM), delivering specific wavelengths of red light to retinal tissue to stimulate cellular energy production and support retinal cell function. By stimulating energy production in compromised cells, PBM helps improve cellular performance and may slow functional decline associated with Dry AMD.
In the LIGHTSITE III clinical trial, approximately 55% of treated patients gained at least five letters in visual acuity at 13 months, with data supporting both safety and sustained visual benefit.
Early diagnosis and ongoing monitoring are critical in managing Dry AMD. Our retina specialists provide individualized evaluation and treatment planning based on each patient’s clinical findings and risk factors to optimize long-term visual outcomes.
Each non-invasive treatment session is painless and typically completed in approximately 15 minutes.
Most patients complete their recommended treatment plan in an average of nine sessions.
Many patients begin to notice improvements in visual acuity and stabilization of AMD progression within five weeks.*
